EndoLIF is a 3D printed titanium alloy that is developed using special electron beam melting (EBM) technology.
The system has a porous surface with a diamond cell structure, providing an optimal base for cell proliferation and bone growth.
Filled with an autogenous bone, the system’s two large implant graft windows allow for bridging bone to further support fusion.
EndoLIF On-Cage implant enables surgeons to use a mini-open or an inter-muscular approach into the intervertebral disc space, allowing for endoscopic-assisted fusion.
The intermuscular approach is similar to a mini-transforaminal lumbar interbody fusion (TLIF) approach.
In July, the company secured 510(k) approval from US Food and Drug Administration (FDA) for the Endoscopic Lumbar Interbody Fusion or EndoLIF On-Cage implant. It also received approval from the FDA for Percusys percutaneous screw-rod system at the start of the year.
The company’s iLESSYS Delta system can be used for dorsal and dorso-lateral treatment of central spinal canal stenosis.
The instrument set comprises newly developed tools, which allow an extensive and tissue-sparing decompression.
A new endoscope with a 6mm working channel enables the use of large shaver blades developed for bone and tissue resection and other instruments can be used under full endoscopic view.
Joimax CEO Wolfgang Ries said: “Albert Telfeian and Jian Shen will be the first spinal surgeons in the US to perform surgeries with the new iLESSYS Delta endoscopic technology and the EndoLIF On-Cage implants.”
“With the new EndoLIF programme, combined with the TESSYS technology, and now the iLESSYS Delta, Joimax offers complete endoscopic solutions for spinal decompression, stabilisation and fusion.”
The company is exhibiting the EndoLIF system at the 30th Annual North American Spine Society (NASS) meeting in Chicago, which is being held from 14-17 October.
Image: Joimax EndoLIF On-Cage implant. Photo: courtesy of Business Wire.